IOVA Insider Trading

Insider Ownership Percentage: 12.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $503,000.00

Iovance Biotherapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Iovance Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal Insider BuyingTotal Insider Selling

Iovance Biotherapeutics Share Price & Price History

Current Price: $5.78
Price Change: Price Increase of +0.17 (3.03%)
As of 02/21/2025 05:00 PM ET

This chart shows the closing price history over time for IOVA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFeb$5.78Closing price on 02/22/25:

SEC Filings (Institutional Ownership Changes) for Iovance Biotherapeutics (NASDAQ:IOVA)

77.03% of Iovance Biotherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IOVA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$115Mbought$47MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
Iovance Biotherapeutics logo
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Read More on Iovance Biotherapeutics

Today's Range

Now: $5.78
Low: $5.68
High: $6.09

50 Day Range

MA: $6.44
Low: $5.29
High: $7.84

52 Week Range

Now: $5.78
Low: $5.05
High: $18.33

Volume

10,890,669 shs

Average Volume

6,926,114 shs

Market Capitalization

$1.76 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.53

Who are the company insiders with the largest holdings of Iovance Biotherapeutics?

Iovance Biotherapeutics' top insider shareholders include:
  1. Wayne P Rothbaum (Director)
  2. Merrill A Mcpeak (Director)
  3. Ryan D Maynard (Director)
Learn More about top insider investors at Iovance Biotherapeutics.

Who are the major institutional investors of Iovance Biotherapeutics?

Iovance Biotherapeutics' top institutional shareholders include:
  1. Vanguard Group Inc. — 9.03%
  2. Hood River Capital Management LLC — 2.95%
  3. Soleus Capital Management L.P. — 2.15%
  4. Geode Capital Management LLC — 1.93%
  5. T. Rowe Price Investment Management Inc. — 1.91%
  6. Long Focus Capital Management LLC — 1.68%
Learn More about top institutional investors of Iovance Biotherapeutics stock.

Which major investors are selling Iovance Biotherapeutics stock?

During the last quarter, IOVA stock was sold by these institutional investors:
  1. Soleus Capital Management L.P.
  2. Bank of America Corp DE
  3. Avoro Capital Advisors LLC
  4. JPMorgan Chase & Co.
  5. Ameriprise Financial Inc.
  6. Price T Rowe Associates Inc. MD
  7. Principal Financial Group Inc.
  8. Schonfeld Strategic Advisors LLC

Which major investors are buying Iovance Biotherapeutics stock?

During the last quarter, IOVA stock was acquired by institutional investors including:
  1. Man Group plc
  2. Assenagon Asset Management S.A.
  3. Raymond James Financial Inc.
  4. Susquehanna International Group LLP
  5. Marshall Wace LLP
  6. B Group Inc.
  7. Stempoint Capital LP
  8. Hood River Capital Management LLC
Within the last year, these company insiders have bought Iovance Biotherapeutics stock:
  1. Wayne P Rothbaum (Director)
  2. Merrill A Mcpeak (Director)
Learn More investors buying Iovance Biotherapeutics stock.